Oncolytics Biotech庐 Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage immunotherapy company focused on pelareorep development, has scheduled its 2025 Annual General Meeting for August 8, 2025, at 10:00 a.m. ET. The meeting will be held virtually, with CEO Jared Kelly providing a corporate update and discussing strategic milestones for 2025 after the formal shareholder voting.
The company will also release its second quarter 2025 financial results before market opening on the same day. Shareholders can access detailed voting information through the Management Information Circular dated June 18, 2025, available on the company's website and in securities filings.
Oncolytics Biotech (NASDAQ: ONCY), un'azienda di immunoterapia in fase clinica focalizzata sullo sviluppo di pelareorep, ha programmato la sua Assemblea Generale Annuale 2025 per l'8 agosto 2025 alle 10:00 ET. L'incontro si terr脿 in modalit脿 virtuale, durante il quale il CEO Jared Kelly fornir脿 un aggiornamento aziendale e discuter脿 i traguardi strategici per il 2025 dopo la votazione formale degli azionisti.
La societ脿 pubblicher脿 inoltre i risultati finanziari del secondo trimestre 2025 prima dell'apertura del mercato nello stesso giorno. Gli azionisti potranno consultare le informazioni dettagliate sulla votazione tramite il Circolare Informativo per la Gestione datato 18 giugno 2025, disponibile sul sito web dell'azienda e nei documenti ufficiali.
Oncolytics Biotech (NASDAQ: ONCY), una empresa de inmunoterapia en fase cl铆nica centrada en el desarrollo de pelareorep, ha programado su Junta General Anual 2025 para el 8 de agosto de 2025 a las 10:00 a.m. ET. La reuni贸n se llevar谩 a cabo de manera virtual, donde el CEO Jared Kelly ofrecer谩 una actualizaci贸n corporativa y discutir谩 los hitos estrat茅gicos para 2025 tras la votaci贸n formal de los accionistas.
La compa帽铆a tambi茅n publicar谩 sus resultados financieros del segundo trimestre de 2025 antes de la apertura del mercado el mismo d铆a. Los accionistas podr谩n acceder a informaci贸n detallada sobre la votaci贸n a trav茅s del Circular de Informaci贸n de Gesti贸n fechado el 18 de junio de 2025, disponible en el sitio web de la empresa y en los archivos de valores.
Oncolytics Biotech (NASDAQ: ONCY)電� 韼犽澕霠堨槫霠� 臧滊皽鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠 氅挫棴旃橂 須岇偓搿�, 2025雲� 鞐半 欤检＜齑濏殞毳� 2025雲� 8鞗� 8鞚� 鞓れ爠 10鞁�(霃欕秬鞁滉皠)鞐� 臧滌禍頃� 鞓堨爼鞛呺媹雼�. 須岇潣電� 鞓澕鞚胳溂搿� 歆勴枆霅橂┌, CEO Jared Kelly臧� 瓿奠嫕 欤检＜ 韴憸 頉� 旮办梾 順勴櫓 鞐呺嵃鞚错姼鞕� 2025雲� 鞝勲灥鞝� 鞚挫爼響滌棎 雽�頃� 雲检潣頃� 鞓堨爼鞛呺媹雼�.
臧欖潃 雮� 鞁滌灔 臧滌灔 鞝�, 須岇偓電� 2025雲� 2攵勱赴 鞛 瓴瓣臣霃� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 欤检＜霌れ潃 2025雲� 6鞗� 18鞚检瀽 瓴届榿 鞝曤炒 靹滍暅鞚� 韱淀暣 鞛愳劯頃� 韴憸 鞝曤炒毳� 須岇偓 鞗轨偓鞚错姼鞕� 歃濌秾 鞁犼碃靹滌棎靹� 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Oncolytics Biotech (NASDAQ : ONCY), une soci茅t茅 d'immunoth茅rapie en phase clinique sp茅cialis茅e dans le d茅veloppement de pelareorep, a programm茅 son Assembl茅e G茅n茅rale Annuelle 2025 pour le 8 ao没t 2025 脿 10h00 ET. La r茅union se tiendra virtuellement, avec le PDG Jared Kelly qui pr茅sentera une mise 脿 jour de l'entreprise et discutera des 茅tapes strat茅giques pour 2025 apr猫s le vote formel des actionnaires.
La soci茅t茅 publiera 茅galement ses r茅sultats financiers du deuxi猫me trimestre 2025 avant l'ouverture du march茅 le m锚me jour. Les actionnaires pourront acc茅der aux informations d茅taill茅es sur le vote via la Circulaire d'Information de Gestion dat茅e du 18 juin 2025, disponible sur le site web de l'entreprise et dans les d茅p么ts r茅glementaires.
Oncolytics Biotech (NASDAQ: ONCY), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf die Entwicklung von Pelareorep, hat seine Jahreshauptversammlung 2025 f眉r den 8. August 2025 um 10:00 Uhr ET angesetzt. Die Versammlung findet virtuell statt, wobei CEO Jared Kelly nach der formellen Abstimmung der Aktion盲re ein Unternehmensupdate und die strategischen Meilensteine f眉r 2025 vorstellen wird.
Das Unternehmen wird am selben Tag vor Markter枚ffnung die Finanzergebnisse f眉r das zweite Quartal 2025 ver枚ffentlichen. Aktion盲re k枚nnen detaillierte Abstimmungsinformationen 眉ber den am 18. Juni 2025 datierten Management-Informationskreis auf der Unternehmenswebsite und in den Wertpapierunterlagen einsehen.
- None.
- None.
The management team will provide a brief corporate update after the formal portion of the shareholder meeting
听
听
To access the Meeting as a guest only (non-voting attendee):
- Visit the webcast site:听
- Click the button "I am a Guest" and complete the form
- If necessary, provide the case-sensitive password: onc2025
Information on how to vote your shares by proxy and attend the Meeting as a shareholder is available in the Company's most recent Management Information Circular (the "Circular") dated June 18, 2025. The Circular is available on the Reports page of the investor relations section of the Company's website at and in Canadian and American securities filings.
Registered shareholders (who have not appointed a proxyholder) and duly appointed proxyholders (including non-registered shareholders who appoint themselves as proxyholders) will be able to virtually attend the Meeting and vote in real-time, provided they are connected to the internet. Non-registered shareholders who have not properly appointed themselves as proxyholder will be able to attend the Meeting as guests but will not be able to vote at the Meeting.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in pancreatic and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic breast and pancreatic cancers, both of which have received Fast Track designation from the FDA. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit:听听or follow the company on social media on and on X @.
Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg
Company Contact
Jon Patton
Director of IR & Communication
[email protected]
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
[email protected]
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
[email protected]
View original content to download multimedia:
SOURCE Oncolytics Biotech庐 Inc.
FAQ
When is Oncolytics Biotech (ONCY) 2025 Annual General Meeting?
How can shareholders attend the ONCY virtual Annual General Meeting 2025?
When will Oncolytics Biotech (ONCY) release Q2 2025 earnings?
Who will present at the Oncolytics Biotech 2025 Annual Meeting?
